Insider Transactions in Q2 2024 at Inhibrx Biosciences, Inc. (INXB)
Insider Transaction List (Q2 2024)
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Jun 24
2024
|
Jon Faiz Kayyem Director |
BUY
Bona fide gift
|
Indirect |
20,000
+38.1%
|
-
|
|
Jun 24
2024
|
Jon Faiz Kayyem Director |
SELL
Bona fide gift
|
Indirect |
89,050
-7.74%
|
-
|
|
Jun 05
2024
|
Jon Faiz Kayyem Director |
BUY
Open market or private purchase
|
Indirect |
57,549
+2.42%
|
$978,333
$17.56 P/Share
|
|
Jun 04
2024
|
Jon Faiz Kayyem Director |
BUY
Open market or private purchase
|
Indirect |
89,063
+3.94%
|
$1,514,071
$17.84 P/Share
|
|
Jun 03
2024
|
Jon Faiz Kayyem Director |
BUY
Open market or private purchase
|
Indirect |
127,530
+6.13%
|
$2,168,010
$17.26 P/Share
|
|
May 31
2024
|
Jon Faiz Kayyem Director |
BUY
Open market or private purchase
|
Indirect |
70,193
+7.42%
|
$1,123,088
$16.14 P/Share
|
|
May 29
2024
|
Inhibrx, Inc. |
SELL
Other acquisition or disposition
|
Direct |
13,316,140
-92.0%
|
-
|
|
May 29
2024
|
Brendan P. Eckelman Chief Scientific Officer |
BUY
Grant, award, or other acquisition
|
Indirect |
513,888
+50.0%
|
-
|
|
May 29
2024
|
Douglas Forsyth Director |
BUY
Grant, award, or other acquisition
|
Indirect |
149,564
+50.0%
|
-
|
|
May 29
2024
|
Jon Faiz Kayyem Director |
BUY
Grant, award, or other acquisition
|
Indirect |
818,575
+50.0%
|
-
|
|
May 29
2024
|
Mark Lappe Chief Executive Officer |
BUY
Grant, award, or other acquisition
|
Indirect |
761,413
+50.0%
|
-
|